The Departments of Anesthesiology and Neurology hosts: “Perivascular Spaces in the Brain & Contributions to Pathology of Cerebral Small Vessel Disease”

Perivascular space and cerebral small vessel disease mini-symposium March 24th in the Brady Memorial Auditorium 1:30-4:30pm

The panel will feature the following Speakers:

- **Keynote Speaker: Joanna M. Wardlaw** (Professor of Applied Neuroimaging and Director of Edinburgh Imaging, University of Edinburgh) “Perivascular Spaces in the Brain: Anatomy, Physiology, and Contributions to Pathology of Small Vessel Disease”
- **Jaime Grutzendler, MD** (Professor of Neurology and Neuroscience): “Optical Interrogation of Neurovascular and Myelin Pathophysiology in the Live Mammalian Brain”
- **Miriam Treggiari, MD PhD** (Professor of Anesthesiology): “Delayed cerebral ischemia in SAH - mechanisms and opportunities for intervention”
- **Keynote Speaker Philip Bath** (Professor of Stroke Medicine, University of Nottingham): “Pharmacological treatment and prevention of cerebral small vessel disease: a review of potential interventions”

**Speakers:**

Joanna Wardlaw, MD FRCR FRCP FMedSci FRSE CBE  
Professor of Applied Neuroimaging and Director of Edinburgh Imaging  
University of Edinburgh, UK

Jaime Grutzendler, MD  
Professor of Neurology and Neuroscience  
Director, Center for Experimental Neuroimaging  
Yale School of Medicine, New Haven

Miriam Treggiari, MD, PhD, MPH  
Professor of Anesthesiology, Vice Chair of Clinical Research, Yale School of Medicine, New Haven

Phillip Bath, M.D., F.R.C.P., FMedSci  
Professor of Stroke Medicine  
University of Nottingham, UK

**Contacts:** Jennifer Vissagio [Jennifer.vissagio@yale.edu](mailto:Jennifer.vissagio@yale.edu) 203 785 3358

**Host Organizations:** Anesthesiology and Neurology

**Precis:** Cerebral small vessel disease (cSVD) are a group of disorders that result from pathological alteration of the small blood vessels in the brain and rank as the most common pathology in vascular dementia. Of the nearly 35-36 million people that are estimated to suffer from dementia worldwide, up to 65% have an cSVD component. Unfortunately, the prevalence of SVD is increasing and effective disease-modifying interventions are yet to be found. In recent years, there has been tremendous growth in new diagnostic information, a greater understanding of cSVD risk factors as well as instigation of new large clinical trials of repurposed drugs in cSVD to prevent dementia and stroke.

**Moderator:** Helene Benveniste, MD, PhD